Broad-based Q2 growth and raised 2026 guidance were supported by Sterigenics momentum, but Nordion timing shifts and elevated investment remain key watchpoints.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-08-06 |
| Length | 53 minutes |
| EPS | $0.24 |
| EPS consensus | $0.22 |
| Revenue | $321.4M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY25
All SHC earnings ยท Back to SHC overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.